WAYNE, Pa., Oct. 7, 2014 /PRNewswire/ -- Ryan &
Maniskas, LLP is investigating potential claims against the board
of directors of Durata Therapeutics, Inc. ("Durata" or the
"Company") (NASDAQ: DRTX) concerning possible breaches of fiduciary
duty and other violations of law related to the Company's efforts
to sell the Company to Actavis plc in a transaction valued at
approximately $675 million.
If you own shares of Durata and would like to learn more about
this class action or if you wish to discuss these matters and have
any questions concerning this announcement or your rights, contact
Richard A. Maniskas, Esquire
toll-free at (877) 316-3218 or to sign up online, visit:
www.rmclasslaw.com/cases/drtx. You may also email Mr.
Maniskas at rmaniskas@rmclasslaw.com.
Under the terms of the agreement, shareholders of Durata would
receive $23.00 in cash, and up to
$5.00 per share in a Contingent Value
Right, for each share of Durata they own.
Our investigation concerns possible breaches of fiduciary duty
and other violations of state law by the Board of Directors of
Durata for not acting in the Company's shareholders' best interests
in connection with the sale process.
Ryan & Maniskas, LLP is a national shareholder litigation
firm. Ryan & Maniskas, LLP is devoted to protecting the
interests of individual and institutional investors in shareholder
actions in state and federal courts nationwide. To learn more
about the class action process, please visit:
www.rmclasslaw.com.
CONTACT: Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old
Eagle School Rd., Suite 311
Wayne, PA
19087
877-316-3218
www.rmclasslaw.com/cases/drtx
rmaniskas@rmclasslaw.com
Logo -
http://photos.prnewswire.com/prnh/20121112/MM11729LOGO
SOURCE Ryan & Maniskas, LLP